Be an Early Applicant
The Role
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In May 2024, Lycia Therapeutics completed a $106.6 million Series C financing to advance its pipeline of LYTAC extracellular protein degraders to the clinic. Lycia is headquartered in South San Francisco.
Visit https://lyciatx.com/ for more information.
Lycia Therapeutics is seeking a highly motivated and detail-oriented Research Associate II/Senior Research Associate I to join the Biologics team. The successful candidate will be responsible for the generation and characterization of molecules to support early discovery research efforts. This individual will work cross functionally as part of an innovative research organization to help advance molecules to the clinic. Hands-on experience with protein purification and characterization techniques is required.
Key Responsibilities:
- Conduct protein characterization using SDS-PAGE, HPLC, LC/MS, DLS, and other biophysical/analytical methods.
- Generate bispecific antibodies through controlled Fab-arm exchange (cFAE).
- Execute secondary protein purification (IEX, SEC, HIC) when necessary.
- Biotinylation and fluorescent dye conjugation of antibodies and proteins.
- Conducts biolayer interferometry (BLI) assays to evaluate antibody-protein interactions.
- Prepare solutions for binding assessments and in vivo studies through formulation and concentration adjustment.
- Update and maintain protein inventories as well as accurate and timely documentation of experimental work in electronic laboratory notebooks (ELNs).
- Contribute to troubleshooting processes, data analysis, and interpretation.
- Opportunity to represent functional area through presentation of data during research team meetings or broader company-wide meetings
- Conducts routine maintenance, calibration, and troubleshooting of laboratory instruments as needed.
Requirements:
- BS in Biology, Biochemistry, or related field with at least 2+ years of relevant experience OR MS with 0+ years of relevant experience. Previous industry experience is strongly preferred.
- Proficiency with FPLC systems (e.g., AKTA) and associated software (e.g., Unicorn).
- Experience in characterizing recombinant proteins, particularly monoclonal/bispecific antibodies, and associated analytical techniques (SDS-PAGE, HPLC, LC/MS, DLS, BLI).
- Basic understanding of protein conjugation technologies (NHS chemistry, enzymatic conjugation, fluorescent dye labeling) and related QC is a plus.
- Demonstrates strong organizational skills and meticulous attention to detail to manage experimental workflows, while effectively communicating findings across multidisciplinary teams.
- Ability to work both independently and collaboratively in a team-oriented research environment.
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Lycia and other biotech companies have recently noticed an increase in email and social media scams targeting job candidates in our industry. Please note Lycia will post any legitimate job openings directly on our website or through our recruitment partner, Lever. If you wish to verify the legitimacy of a job opening, you may contact us.
Similar Jobs
Get Personalized Job Insights.
Our AI-powered fit analysis compares your resume with a job listing so you know if your skills & experience align.
Success! Refresh the page to see how your skills align with this role.
The Company
What We Do
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
